BioCentury
BioCentury
ARTICLE | Tools & Techniques

Precision for pancreatic cancer

How new tumor profiling methods could bring precision to pancreatic cancer

Allison Johnson, Staff Writer
September 21, 2018 1:21 AM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Cold Spring Harbor Laboratory

Dana-Farber Cancer Institute

Pancreatic Cancer Action Network

Strata Oncology Inc.

BCIQ Target Profiles

BRAF

Breast cancer 1 early onset (BRCA1)

Breast cancer 2 early onset (BRCA2)

Cyclin dependent kinase inhibitor 2A (CDKN2A) (INK4a) (ARF) (p16INK4a)

K-Ras (KRAS)

MAP kinase kinase 1 (MAP2K1) (MEK1)

Neuregulin 1 (NRG1) (HRG1)

BCIQ Company Profiles

Cold Spring Harbor Laboratory

Dana-Farber Cancer Institute

Pancreatic Cancer Action Network

Strata Oncology Inc.

BCIQ Target Profiles

BRAF

Breast cancer 1 early onset (BRCA1)

Breast cancer 2 early onset (BRCA2)

Cyclin dependent kinase inhibitor 2A (CDKN2A) (INK4a) (ARF) (p16INK4a)

K-Ras (KRAS)

MAP kinase kinase 1 (MAP2K1) (MEK1)

Neuregulin 1 (NRG1) (HRG1)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS